The PAtient Preference Analysis of Yearly Follow-up After PCI (PAPAYA)

Overview

The purpose of this study is to determine the preference of patients regarding the approach for follow-up after percutaneous coronary intervention (PCI) procedures. We hypothesize that patients prefer questionnaires for annual follow-up assessment when compared to telephone or email.

Full Title of Study: “What Patients Really Want – Patient Preferences Regarding Annual Follow-up After Medical Interventions: The PAPAYA Study”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: August 2014

Detailed Description

Rationale: Assessment and reporting of long-term clinical follow-up after medical interventions is essential for transparency of medical care and its quality improvement. However follow-up adherence is a serious challenge in clinical trials. Taking the patient preference of the mode of follow-up into account is likely to enhance trial adherence, reduce withdrawals, and facilitate a longer follow-up duration. No data on patient preference of annual follow-up have been reported. Objective: To investigate the patient preference of approach to obtain follow-up information after percutaneous coronary intervention (PCI) Study design: Single-center, prospective, observational registry Study population: All patients enrolled in the percutaneous coronary intervention studies TWENTE trial (a broad study population reflecting real-world PCI patients) and DUTCH PEERS trial (an all-comers population), who were treated at Thoraxcentrum Twente in Enschede between June 2008 and May 2012 Intervention: All subjects will receive a questionnaire with questions regarding their preference with regards to the approach of acquiring follow-up information after PCI. Main study endpoints: – The primary endpoint is the patient preference on how to be approached for annual follow-up after PCI procedures. – Secondary endpoints include 1. least preferred approach of follow-up 2. the preferred number of follow-up moments per year 3. the from the patients' perspective maximum acceptable number of questions to be answered 4. the assessment of potential relationships between the most and least preferred approach of assessment and patient age, gender urgency of PCI treatment, and history of previous revascularizations

Arms, Groups and Cohorts

  • Responders
    • Responding participants
  • Non-responders
    • Non-responding participants

Clinical Trial Outcome Measures

Primary Measures

  • Assessment of preferred approach for annual follow-up after PCI
    • Time Frame: 1 year

Secondary Measures

  • Least preferred approach for follow up
    • Time Frame: 1 year
  • Maximum acceptable number of questions to be answered
    • Time Frame: 1 year

Participating in This Clinical Trial

Inclusion Criteria

  • All patients enrolled in the TWENTE trial and DUTCH PEERS trial (an all-comers population, who were treated at Thoraxcentrum Twente in Enschede between June 2008 and May 2012 Exclusion Criteria:

  • Patients who had withdrawn their consent for participation in the TWENTE and DUTCH PEERS trials, respectively. Patients who passed away during follow-up could obviously not be approached for further questioning.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Thorax Centrum Twente
  • Provider of Information About this Clinical Study
    • Principal Investigator: Clemens von Birgelen, Professor – Thorax Centrum Twente
  • Overall Official(s)
    • Clemens von Birgelen, MD,PhD,Prof, Principal Investigator, Thorax Centrum Twente

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.